Loading…

Cerebrospinal fluid oligoclonal bands in Chinese patients with multiple sclerosis: the prevalence and its association with clinical features

Cerebrospinal fluid oligoclonal band (CSF-OCB) is an established biomarker in diagnosing multiple sclerosis (MS), however, there are no nationwide data on CSF-OCB prevalence and its diagnostic performance in Chinese MS patients, especially in the virtue of common standard operation procedure (SOP)....

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-11, Vol.14, p.1280020-1280020
Main Authors: Zhang, Xiang, Hao, Hongjun, Jin, Tao, Qiu, Wei, Yang, Huan, Xue, Qun, Yin, Jian, Shi, Ziyan, Yu, Hai, Ji, Xiaopei, Sun, Xiaobo, Zeng, Qiuming, Liu, Xiaoni, Wang, Jingguo, Li, Huining, He, Xiaoyan, Yang, Jing, Li, Yarong, Liu, Shuangshuang, Lau, Alexander Y, Gao, Feng, Hu, Shimin, Chu, Shuguang, Ding, Ding, Zhou, Hongyu, Li, Haifeng, Chen, Xiangjun
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c420t-c9ce5813488c48d5fea4c10c30e7ad3fcd8b67ef68479a024b1ca784d32b62fc3
container_end_page 1280020
container_issue
container_start_page 1280020
container_title Frontiers in immunology
container_volume 14
creator Zhang, Xiang
Hao, Hongjun
Jin, Tao
Qiu, Wei
Yang, Huan
Xue, Qun
Yin, Jian
Shi, Ziyan
Yu, Hai
Ji, Xiaopei
Sun, Xiaobo
Zeng, Qiuming
Liu, Xiaoni
Wang, Jingguo
Li, Huining
He, Xiaoyan
Yang, Jing
Li, Yarong
Liu, Shuangshuang
Lau, Alexander Y
Gao, Feng
Hu, Shimin
Chu, Shuguang
Ding, Ding
Zhou, Hongyu
Li, Haifeng
Chen, Xiangjun
description Cerebrospinal fluid oligoclonal band (CSF-OCB) is an established biomarker in diagnosing multiple sclerosis (MS), however, there are no nationwide data on CSF-OCB prevalence and its diagnostic performance in Chinese MS patients, especially in the virtue of common standard operation procedure (SOP). With a consensus SOP and the same isoelectric focusing system, we conducted a nationwide multi-center study on OCB status in consecutively, and recruited 483 MS patients and 880 non-MS patients, including neuro-inflammatory diseases (NID, n = 595) and non-inflammatory neurological diseases (NIND, n=285). Using a standardized case report form (CRF) to collect the clinical, radiological, immunological, and CSF data, we explored the association of CSF-OCB positivity with patient characters and the diagnostic performance of CSF-OCB in Chinese MS patients. Prospective source data collection, and retrospective data acquisition and statistical data analysis were used. 369 (76.4%) MS patients were OCB-positive, while 109 NID patients (18.3%) and 6 NIND patients (2.1%) were OCB-positive, respectively. Time from symptom onset to diagnosis was significantly shorter in OCB-positive than that in OCB-negative MS patients (13.2 vs 23.7 months, P=0.020). The prevalence of CSF-OCB in Chinese MS patients was significantly higher in high-latitude regions (41°-50°N)(P=0.016), and at high altitudes (>1000m)(P=0.025). The diagnostic performance of CSF-OCB differentiating MS from non-MS patients yielded a sensitivity of 76%, a specificity of 87%. The nationwide prevalence of CSF-OCB was 76.4% in Chinese MS patients, and demonstrated a good diagnostic performance in differentiating MS from other CNS diseases. The CSF-OCB prevalence showed a correlation with high latitude and altitude in Chinese MS patients.
doi_str_mv 10.3389/fimmu.2023.1280020
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a1eb21cad01447c4b7c29ec683ffe406</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a1eb21cad01447c4b7c29ec683ffe406</doaj_id><sourcerecordid>2896805451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-c9ce5813488c48d5fea4c10c30e7ad3fcd8b67ef68479a024b1ca784d32b62fc3</originalsourceid><addsrcrecordid>eNpVks9u1DAQxiMEolXpC3BAPnLZxf-SOFwQWkFbqRIXOFvOZLI7lWMvdlLUd-Ch8XaXqvXF1vj7fmOPvqp6L_haKdN9GmmalrXkUq2FNJxL_qo6F02jV0pK_frZ-ay6zPmOl6U7pVT9tjpThquat-159XeDCfsU856C82z0Cw0setpG8PFQ6V0YMqPANjsKmJHt3UwY5sz-0Lxj0-Jn2ntkGTwWDOXPbN4VVcJ75zEAsgJgVPQu5whU3DEcveApEBy6opuXhPld9WZ0PuPlab-ofn3_9nNzvbr9cXWz-Xq7Ai35vIIOsDZCaWNAm6Eudg2Cg-LYukGNMJi-aXFsjG47x6XuBbjW6EHJvpEjqIvq5sgdoruz-0STSw82OrKPhZi21qWZyo-sE9jLYh-40LoF3bcgO4TGqHFEzZvC-nJk7Zd-wgHKaJLzL6AvbwLt7DbeW8Eb02rOC-HjiZDi7wXzbCfKgN67gHHJVpquMbzWtShSeZRCGXVOOD71EdweYmEfY2EPsbCnWBTTh-cvfLL8D4H6B2ajuVg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2896805451</pqid></control><display><type>article</type><title>Cerebrospinal fluid oligoclonal bands in Chinese patients with multiple sclerosis: the prevalence and its association with clinical features</title><source>PubMed (Medline)</source><creator>Zhang, Xiang ; Hao, Hongjun ; Jin, Tao ; Qiu, Wei ; Yang, Huan ; Xue, Qun ; Yin, Jian ; Shi, Ziyan ; Yu, Hai ; Ji, Xiaopei ; Sun, Xiaobo ; Zeng, Qiuming ; Liu, Xiaoni ; Wang, Jingguo ; Li, Huining ; He, Xiaoyan ; Yang, Jing ; Li, Yarong ; Liu, Shuangshuang ; Lau, Alexander Y ; Gao, Feng ; Hu, Shimin ; Chu, Shuguang ; Ding, Ding ; Zhou, Hongyu ; Li, Haifeng ; Chen, Xiangjun</creator><creatorcontrib>Zhang, Xiang ; Hao, Hongjun ; Jin, Tao ; Qiu, Wei ; Yang, Huan ; Xue, Qun ; Yin, Jian ; Shi, Ziyan ; Yu, Hai ; Ji, Xiaopei ; Sun, Xiaobo ; Zeng, Qiuming ; Liu, Xiaoni ; Wang, Jingguo ; Li, Huining ; He, Xiaoyan ; Yang, Jing ; Li, Yarong ; Liu, Shuangshuang ; Lau, Alexander Y ; Gao, Feng ; Hu, Shimin ; Chu, Shuguang ; Ding, Ding ; Zhou, Hongyu ; Li, Haifeng ; Chen, Xiangjun</creatorcontrib><description>Cerebrospinal fluid oligoclonal band (CSF-OCB) is an established biomarker in diagnosing multiple sclerosis (MS), however, there are no nationwide data on CSF-OCB prevalence and its diagnostic performance in Chinese MS patients, especially in the virtue of common standard operation procedure (SOP). With a consensus SOP and the same isoelectric focusing system, we conducted a nationwide multi-center study on OCB status in consecutively, and recruited 483 MS patients and 880 non-MS patients, including neuro-inflammatory diseases (NID, n = 595) and non-inflammatory neurological diseases (NIND, n=285). Using a standardized case report form (CRF) to collect the clinical, radiological, immunological, and CSF data, we explored the association of CSF-OCB positivity with patient characters and the diagnostic performance of CSF-OCB in Chinese MS patients. Prospective source data collection, and retrospective data acquisition and statistical data analysis were used. 369 (76.4%) MS patients were OCB-positive, while 109 NID patients (18.3%) and 6 NIND patients (2.1%) were OCB-positive, respectively. Time from symptom onset to diagnosis was significantly shorter in OCB-positive than that in OCB-negative MS patients (13.2 vs 23.7 months, P=0.020). The prevalence of CSF-OCB in Chinese MS patients was significantly higher in high-latitude regions (41°-50°N)(P=0.016), and at high altitudes (&gt;1000m)(P=0.025). The diagnostic performance of CSF-OCB differentiating MS from non-MS patients yielded a sensitivity of 76%, a specificity of 87%. The nationwide prevalence of CSF-OCB was 76.4% in Chinese MS patients, and demonstrated a good diagnostic performance in differentiating MS from other CNS diseases. The CSF-OCB prevalence showed a correlation with high latitude and altitude in Chinese MS patients.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2023.1280020</identifier><identifier>PMID: 38035077</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>cerebrospinal fluid ; China ; diagnostic performance ; East Asian People ; Humans ; Immunology ; multiple sclerosis ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - epidemiology ; oligoclonal bands ; Oligoclonal Bands - cerebrospinal fluid ; Prevalence ; Prospective Studies ; Retrospective Studies</subject><ispartof>Frontiers in immunology, 2023-11, Vol.14, p.1280020-1280020</ispartof><rights>Copyright © 2023 Zhang, Hao, Jin, Qiu, Yang, Xue, Yin, Shi, Yu, Ji, Sun, Zeng, Liu, Wang, Li, He, Yang, Li, Liu, Lau, Gao, Hu, Chu, Ding, Zhou, Li and Chen.</rights><rights>Copyright © 2023 Zhang, Hao, Jin, Qiu, Yang, Xue, Yin, Shi, Yu, Ji, Sun, Zeng, Liu, Wang, Li, He, Yang, Li, Liu, Lau, Gao, Hu, Chu, Ding, Zhou, Li and Chen 2023 Zhang, Hao, Jin, Qiu, Yang, Xue, Yin, Shi, Yu, Ji, Sun, Zeng, Liu, Wang, Li, He, Yang, Li, Liu, Lau, Gao, Hu, Chu, Ding, Zhou, Li and Chen</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c420t-c9ce5813488c48d5fea4c10c30e7ad3fcd8b67ef68479a024b1ca784d32b62fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687400/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687400/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38035077$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Xiang</creatorcontrib><creatorcontrib>Hao, Hongjun</creatorcontrib><creatorcontrib>Jin, Tao</creatorcontrib><creatorcontrib>Qiu, Wei</creatorcontrib><creatorcontrib>Yang, Huan</creatorcontrib><creatorcontrib>Xue, Qun</creatorcontrib><creatorcontrib>Yin, Jian</creatorcontrib><creatorcontrib>Shi, Ziyan</creatorcontrib><creatorcontrib>Yu, Hai</creatorcontrib><creatorcontrib>Ji, Xiaopei</creatorcontrib><creatorcontrib>Sun, Xiaobo</creatorcontrib><creatorcontrib>Zeng, Qiuming</creatorcontrib><creatorcontrib>Liu, Xiaoni</creatorcontrib><creatorcontrib>Wang, Jingguo</creatorcontrib><creatorcontrib>Li, Huining</creatorcontrib><creatorcontrib>He, Xiaoyan</creatorcontrib><creatorcontrib>Yang, Jing</creatorcontrib><creatorcontrib>Li, Yarong</creatorcontrib><creatorcontrib>Liu, Shuangshuang</creatorcontrib><creatorcontrib>Lau, Alexander Y</creatorcontrib><creatorcontrib>Gao, Feng</creatorcontrib><creatorcontrib>Hu, Shimin</creatorcontrib><creatorcontrib>Chu, Shuguang</creatorcontrib><creatorcontrib>Ding, Ding</creatorcontrib><creatorcontrib>Zhou, Hongyu</creatorcontrib><creatorcontrib>Li, Haifeng</creatorcontrib><creatorcontrib>Chen, Xiangjun</creatorcontrib><title>Cerebrospinal fluid oligoclonal bands in Chinese patients with multiple sclerosis: the prevalence and its association with clinical features</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>Cerebrospinal fluid oligoclonal band (CSF-OCB) is an established biomarker in diagnosing multiple sclerosis (MS), however, there are no nationwide data on CSF-OCB prevalence and its diagnostic performance in Chinese MS patients, especially in the virtue of common standard operation procedure (SOP). With a consensus SOP and the same isoelectric focusing system, we conducted a nationwide multi-center study on OCB status in consecutively, and recruited 483 MS patients and 880 non-MS patients, including neuro-inflammatory diseases (NID, n = 595) and non-inflammatory neurological diseases (NIND, n=285). Using a standardized case report form (CRF) to collect the clinical, radiological, immunological, and CSF data, we explored the association of CSF-OCB positivity with patient characters and the diagnostic performance of CSF-OCB in Chinese MS patients. Prospective source data collection, and retrospective data acquisition and statistical data analysis were used. 369 (76.4%) MS patients were OCB-positive, while 109 NID patients (18.3%) and 6 NIND patients (2.1%) were OCB-positive, respectively. Time from symptom onset to diagnosis was significantly shorter in OCB-positive than that in OCB-negative MS patients (13.2 vs 23.7 months, P=0.020). The prevalence of CSF-OCB in Chinese MS patients was significantly higher in high-latitude regions (41°-50°N)(P=0.016), and at high altitudes (&gt;1000m)(P=0.025). The diagnostic performance of CSF-OCB differentiating MS from non-MS patients yielded a sensitivity of 76%, a specificity of 87%. The nationwide prevalence of CSF-OCB was 76.4% in Chinese MS patients, and demonstrated a good diagnostic performance in differentiating MS from other CNS diseases. The CSF-OCB prevalence showed a correlation with high latitude and altitude in Chinese MS patients.</description><subject>cerebrospinal fluid</subject><subject>China</subject><subject>diagnostic performance</subject><subject>East Asian People</subject><subject>Humans</subject><subject>Immunology</subject><subject>multiple sclerosis</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>oligoclonal bands</subject><subject>Oligoclonal Bands - cerebrospinal fluid</subject><subject>Prevalence</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVks9u1DAQxiMEolXpC3BAPnLZxf-SOFwQWkFbqRIXOFvOZLI7lWMvdlLUd-Ch8XaXqvXF1vj7fmOPvqp6L_haKdN9GmmalrXkUq2FNJxL_qo6F02jV0pK_frZ-ay6zPmOl6U7pVT9tjpThquat-159XeDCfsU856C82z0Cw0setpG8PFQ6V0YMqPANjsKmJHt3UwY5sz-0Lxj0-Jn2ntkGTwWDOXPbN4VVcJ75zEAsgJgVPQu5whU3DEcveApEBy6opuXhPld9WZ0PuPlab-ofn3_9nNzvbr9cXWz-Xq7Ai35vIIOsDZCaWNAm6Eudg2Cg-LYukGNMJi-aXFsjG47x6XuBbjW6EHJvpEjqIvq5sgdoruz-0STSw82OrKPhZi21qWZyo-sE9jLYh-40LoF3bcgO4TGqHFEzZvC-nJk7Zd-wgHKaJLzL6AvbwLt7DbeW8Eb02rOC-HjiZDi7wXzbCfKgN67gHHJVpquMbzWtShSeZRCGXVOOD71EdweYmEfY2EPsbCnWBTTh-cvfLL8D4H6B2ajuVg</recordid><startdate>20231116</startdate><enddate>20231116</enddate><creator>Zhang, Xiang</creator><creator>Hao, Hongjun</creator><creator>Jin, Tao</creator><creator>Qiu, Wei</creator><creator>Yang, Huan</creator><creator>Xue, Qun</creator><creator>Yin, Jian</creator><creator>Shi, Ziyan</creator><creator>Yu, Hai</creator><creator>Ji, Xiaopei</creator><creator>Sun, Xiaobo</creator><creator>Zeng, Qiuming</creator><creator>Liu, Xiaoni</creator><creator>Wang, Jingguo</creator><creator>Li, Huining</creator><creator>He, Xiaoyan</creator><creator>Yang, Jing</creator><creator>Li, Yarong</creator><creator>Liu, Shuangshuang</creator><creator>Lau, Alexander Y</creator><creator>Gao, Feng</creator><creator>Hu, Shimin</creator><creator>Chu, Shuguang</creator><creator>Ding, Ding</creator><creator>Zhou, Hongyu</creator><creator>Li, Haifeng</creator><creator>Chen, Xiangjun</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20231116</creationdate><title>Cerebrospinal fluid oligoclonal bands in Chinese patients with multiple sclerosis: the prevalence and its association with clinical features</title><author>Zhang, Xiang ; Hao, Hongjun ; Jin, Tao ; Qiu, Wei ; Yang, Huan ; Xue, Qun ; Yin, Jian ; Shi, Ziyan ; Yu, Hai ; Ji, Xiaopei ; Sun, Xiaobo ; Zeng, Qiuming ; Liu, Xiaoni ; Wang, Jingguo ; Li, Huining ; He, Xiaoyan ; Yang, Jing ; Li, Yarong ; Liu, Shuangshuang ; Lau, Alexander Y ; Gao, Feng ; Hu, Shimin ; Chu, Shuguang ; Ding, Ding ; Zhou, Hongyu ; Li, Haifeng ; Chen, Xiangjun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-c9ce5813488c48d5fea4c10c30e7ad3fcd8b67ef68479a024b1ca784d32b62fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>cerebrospinal fluid</topic><topic>China</topic><topic>diagnostic performance</topic><topic>East Asian People</topic><topic>Humans</topic><topic>Immunology</topic><topic>multiple sclerosis</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>oligoclonal bands</topic><topic>Oligoclonal Bands - cerebrospinal fluid</topic><topic>Prevalence</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Xiang</creatorcontrib><creatorcontrib>Hao, Hongjun</creatorcontrib><creatorcontrib>Jin, Tao</creatorcontrib><creatorcontrib>Qiu, Wei</creatorcontrib><creatorcontrib>Yang, Huan</creatorcontrib><creatorcontrib>Xue, Qun</creatorcontrib><creatorcontrib>Yin, Jian</creatorcontrib><creatorcontrib>Shi, Ziyan</creatorcontrib><creatorcontrib>Yu, Hai</creatorcontrib><creatorcontrib>Ji, Xiaopei</creatorcontrib><creatorcontrib>Sun, Xiaobo</creatorcontrib><creatorcontrib>Zeng, Qiuming</creatorcontrib><creatorcontrib>Liu, Xiaoni</creatorcontrib><creatorcontrib>Wang, Jingguo</creatorcontrib><creatorcontrib>Li, Huining</creatorcontrib><creatorcontrib>He, Xiaoyan</creatorcontrib><creatorcontrib>Yang, Jing</creatorcontrib><creatorcontrib>Li, Yarong</creatorcontrib><creatorcontrib>Liu, Shuangshuang</creatorcontrib><creatorcontrib>Lau, Alexander Y</creatorcontrib><creatorcontrib>Gao, Feng</creatorcontrib><creatorcontrib>Hu, Shimin</creatorcontrib><creatorcontrib>Chu, Shuguang</creatorcontrib><creatorcontrib>Ding, Ding</creatorcontrib><creatorcontrib>Zhou, Hongyu</creatorcontrib><creatorcontrib>Li, Haifeng</creatorcontrib><creatorcontrib>Chen, Xiangjun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Xiang</au><au>Hao, Hongjun</au><au>Jin, Tao</au><au>Qiu, Wei</au><au>Yang, Huan</au><au>Xue, Qun</au><au>Yin, Jian</au><au>Shi, Ziyan</au><au>Yu, Hai</au><au>Ji, Xiaopei</au><au>Sun, Xiaobo</au><au>Zeng, Qiuming</au><au>Liu, Xiaoni</au><au>Wang, Jingguo</au><au>Li, Huining</au><au>He, Xiaoyan</au><au>Yang, Jing</au><au>Li, Yarong</au><au>Liu, Shuangshuang</au><au>Lau, Alexander Y</au><au>Gao, Feng</au><au>Hu, Shimin</au><au>Chu, Shuguang</au><au>Ding, Ding</au><au>Zhou, Hongyu</au><au>Li, Haifeng</au><au>Chen, Xiangjun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cerebrospinal fluid oligoclonal bands in Chinese patients with multiple sclerosis: the prevalence and its association with clinical features</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2023-11-16</date><risdate>2023</risdate><volume>14</volume><spage>1280020</spage><epage>1280020</epage><pages>1280020-1280020</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>Cerebrospinal fluid oligoclonal band (CSF-OCB) is an established biomarker in diagnosing multiple sclerosis (MS), however, there are no nationwide data on CSF-OCB prevalence and its diagnostic performance in Chinese MS patients, especially in the virtue of common standard operation procedure (SOP). With a consensus SOP and the same isoelectric focusing system, we conducted a nationwide multi-center study on OCB status in consecutively, and recruited 483 MS patients and 880 non-MS patients, including neuro-inflammatory diseases (NID, n = 595) and non-inflammatory neurological diseases (NIND, n=285). Using a standardized case report form (CRF) to collect the clinical, radiological, immunological, and CSF data, we explored the association of CSF-OCB positivity with patient characters and the diagnostic performance of CSF-OCB in Chinese MS patients. Prospective source data collection, and retrospective data acquisition and statistical data analysis were used. 369 (76.4%) MS patients were OCB-positive, while 109 NID patients (18.3%) and 6 NIND patients (2.1%) were OCB-positive, respectively. Time from symptom onset to diagnosis was significantly shorter in OCB-positive than that in OCB-negative MS patients (13.2 vs 23.7 months, P=0.020). The prevalence of CSF-OCB in Chinese MS patients was significantly higher in high-latitude regions (41°-50°N)(P=0.016), and at high altitudes (&gt;1000m)(P=0.025). The diagnostic performance of CSF-OCB differentiating MS from non-MS patients yielded a sensitivity of 76%, a specificity of 87%. The nationwide prevalence of CSF-OCB was 76.4% in Chinese MS patients, and demonstrated a good diagnostic performance in differentiating MS from other CNS diseases. The CSF-OCB prevalence showed a correlation with high latitude and altitude in Chinese MS patients.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>38035077</pmid><doi>10.3389/fimmu.2023.1280020</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3224
ispartof Frontiers in immunology, 2023-11, Vol.14, p.1280020-1280020
issn 1664-3224
1664-3224
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a1eb21cad01447c4b7c29ec683ffe406
source PubMed (Medline)
subjects cerebrospinal fluid
China
diagnostic performance
East Asian People
Humans
Immunology
multiple sclerosis
Multiple Sclerosis - diagnosis
Multiple Sclerosis - epidemiology
oligoclonal bands
Oligoclonal Bands - cerebrospinal fluid
Prevalence
Prospective Studies
Retrospective Studies
title Cerebrospinal fluid oligoclonal bands in Chinese patients with multiple sclerosis: the prevalence and its association with clinical features
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T05%3A20%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cerebrospinal%20fluid%20oligoclonal%20bands%20in%20Chinese%20patients%20with%20multiple%20sclerosis:%20the%20prevalence%20and%20its%20association%20with%20clinical%20features&rft.jtitle=Frontiers%20in%20immunology&rft.au=Zhang,%20Xiang&rft.date=2023-11-16&rft.volume=14&rft.spage=1280020&rft.epage=1280020&rft.pages=1280020-1280020&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2023.1280020&rft_dat=%3Cproquest_doaj_%3E2896805451%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c420t-c9ce5813488c48d5fea4c10c30e7ad3fcd8b67ef68479a024b1ca784d32b62fc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2896805451&rft_id=info:pmid/38035077&rfr_iscdi=true